ФИЗИОЛОГИЧЕСКАЯ СИСТЕМА СОЕДИНИТЕЛЬНОЙ ТКАНИ И ОНКОГЕНЕЗ. II. ЭКСТРАЦЕЛЛЮЛЯРНЫЙ МАТРИКС И МЕТАСТАЗИРОВАНИЕ
Ключові слова:
злокачественные опухоли, метастазирование, экстрацеллюлярный матрикс, эпителиально-мезенхимальный переход, метастатическая ниша, гипоксия, клетки системы иммунитета, ангиогенез.Анотація
Обзор представляет современную информацию о роли внеклеточного компонента — экстрацеллюлярного матрикса (ЭЦМ) — системы соединительной ткани в патогенезе метастазирования. После краткого изложения общих представлений об ЭЦМ с ориентацией преимущественно на работы
последнего десятилетия рассматриваются следующие вопросы: состояние ЭЦМ в условиях гипоксии; участие компонентов ЭЦМ в формировании метастатических ниш; возможные пути влияния ЭЦМ на эпителиально-мезенхимальный переход; характер взаимодействия компонентов
ЭЦМ с клетками системы иммунитета; роль ЭЦМ в ангиогенезе. Изложенные сведения позволяют заключить, что ЭЦМ осуществляет контроль за инвазией и метастазированием опухолевых клеток; его дисрегуляция — важнейший этап метастатического процесса. Уровень современных знаний дает все основания рассматривать изменения ЭЦМ как
важный этап патогенеза опухолевого процесса, а его компоненты — как
мишень для возможного терапевтического воздействия с учетом их роли
в развитии различных опухолей.
Посилання
Fidler IJ. The pathogenesis of cancer metastasis: the «seed and soil» hypothesis revisited. Nat Rev Cancer 2003; 3: 453–8.
Malik R, Lelkes PI, Cukierman E. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends Biotechnol 2015; 33: 230–6.
Cox TR, Rumney RM, Schoof EM, at al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015; 522: 106–10.
Venning FA, Wullkopf L, Erler JT. Targeting ECM disrupts cancer progression. Front Oncol 2015; 5: 224.
Fidler IJ. The biology of brain metastasis: challenges for therapy. Cancer J 2015; 21: 284–93.
Fidler IJ. Commentary on «Tumor Heterogeneity and the Biology of Cancer Invasion and Metastasis». Cancer Res 2016; 76: 3441–2.
Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8 (2): 98–101.
Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011; 21: 107–12.
Langley RR, Fidler IJ. The biology of brain metastasis.Clin Chem 2013; 59: 180–9.
Langley RR, Fidler IJ. The seed and soil hypothesis revisitedthe role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011; 128: 2527–35.
Özdemir B, Hensel J, Secondini C, et al. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches. PLoS One 2014; 9: e114530.
Malik R, Lelkes PI, Cukierman E. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends Biotechnol 2015; 33: 230–6.
Kovács KA, Hegedus B, Kenessey I, et al. Tumor type-specific and skin region-selective metastasis of human cancers: another example of the «seed and soil» hypothesis. Cancer Metastasis Rev 2013; 32: 493–9.
López-Ceballos P, Herrera-Reyes AD, Coombs D, et al. In vivo regulation of integrin turnover by outside-in activation. J Cell Sci 2016; 129: 2912–24.
Xiong J, Balcioglu HE, Danen EH. Integrin signaling in control of tumor growth and progression. Int J Biochem Cell Biol 2013; 45: 1012–5.
Goel HL, Pursell B, Standley C, et al. Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling. J Cell Sci 2012; 125: 497–506.
Fujimaki T, Price JE, Fan D, et al. Selective growth of human melanoma cells in the brain parenchyma of nude mice. Melanoma Res 1996; 6: 363–71.
Fidler IJ, Schackert G, Zhang RD, et al. The biology of melanoma brain metastasis. Cancer Metastasis Rev 1999; 18: 387–400.
Cox TR,Erler JT. Molecular pathways: connecting fibrosis and solid tumor metastasis. Clin Cancer Res 2014; 20: 3637–43.
Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 2014; 15: 786–801.
Hynes RO, Naba A. Overview of the matrisome — an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 2012; 4: a004903.
Nikitovic D, Corsini E, Kouretas D, et al. ROS-major mediators of extracellular matrix remodeling during tumor progression. Food Chem Toxicol 2013; 61: 178–86.
Lu P,WeaverVM,Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196: 395–406.
Miles FL, Sikes RA. Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res 2014; 12: 297–312.
Levental KR, Yu H, Kass L, Lakins JN, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891–906.
Theocharis AD, Skandalis SS, Gialeli C, et al. Extracellular matrix structure. Adv Drug Deliv Rev 2016; 97: 4–27.
Bai C, Yang M, Fan Z, et al. Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma. J Exp Clin Cancer Res 2015; 34: 58.
Multhaupt HA, Leitinger B, Gullberg D, et al. Extracellular matrix component signaling in cancer. Adv Drug Deliv Rev 2016; 97: 28–40.
Seguin L, Desgrosellier JS, Weis SM, et al. Cheresh Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol 2015; 25: 234–40.
Rodriguez A, Karen J, Gardner H, et al. Integrin alpha1beta1 is involved in the differentiation into myofibroblasts in adult reactive tissues in vivo. J Cell Mol Med 2009; 13: 3449–62.
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52–67.
Kim GE, Lee JS, Choi YD, et al. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemicalbased molecular subtypes of breast cancer. BMC Cancer 2014; 14: 959.
Bodnar M, Szylberg L, Kazmierczak W, et al. Differentiated expression of membrane type metalloproteinases (MMP-14, MMP-15) and pro-MMP2 in laryngeal squamous cell carcinoma. A novel mechanism. J Oral Pathol Med 2013; 42: 267–74.
Vosseler S, Lederle W, Airola K, et al.Distinct progression-associated expression of tumor and stromal MMPs in HaCaT skin SCCs correlates with onset of invasion. Int J Cancer 2009; 125: 2296–306.
Huang Y, Yu H, Lei H, et al. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients. Med Oncol 2014; 31: 824.
Wang WS, Chen PM, Wang HS, et al. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 2006; 27: 1113–20.
Бережная НМ. Семейства интерлейкинов: биология ионкогенез. Киев: Наукова думка, 2013. 575 с.
Ogden SR, Noto JM, Allen SS, et al. Matrix metalloproteinase-7 and premalignant host responses in Helicobacter pylori-infected mice. Cancer Res 2010; 70: 30–5.
Dayer C, Stamenkovic I. Recruitment of matrix metalloproteinase-9 (MMP-9) to the fibroblast cell surface by lysyl hydroxylase 3 (LH3) triggers transforming growth factor-β (TGF-β) activation and fibroblast differentiation. J Biol Chem 2015; 290: 13763–78.
Nakamura T, Kuwai T, Kim JS, et al. Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia 2007; 9: 979–86.
Xue Z,Wu X,Chen X, et al. MT3-MMP down-regulation promotes tumorigenesis and correlates to poor prognosis in esophageal squamous cell carcinoma. Cancer Med 2016. doi: 10.1002/cam4.790. [Epub ahead of print].
Morell-Quadreny L, Rubio J, Lopez-Guerrero JA, et al. Disruption of basement membrane, extracellular matrix metalloproteinases and E-cadherin in renal-cell carcinoma. Anticancer Res 2003; 23: 5005–10.
Musumeci G, Magro G, Cardile V, et al. Characterization of matrix metalloproteinase-2 and -9, ADAM-10 and N-cadherin expression in human glioblastoma multiforme. Cell Tissue Res 2015; 362: 45–60.
Foda AA, El-Hawary AK, Aziz AA. Colorectal adenocarcinoma with mucinous component: relation of MMP-13, EGFR, and Ecadherin expressions to clinicopathological features and prognosis. APMIS 2015; 123: 502–8.
Bourguignon LY, Wong G, Earle CA, et al. Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFκB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion. Cytoskeleton (Hoboken) 2011; 68 (12): 671–93.
Heo JH, Song JY, Jeong JY, et al. Fibulin-5 is a tumour suppressor inhibiting cell migration and invasion in ovarian cancer. J Clin Pathol 2016; 69 (2): 109–16.
Lowy CM,OskarssonT. TenascinC in metastasis: a view from the invasive front. Cell Adh Migr 2015; 9: 112–24.
Bedore J, Leask A, Séguin CA. Targeting the extracellular matrix: matricellular proteins regulate cell-extracellular matrix communication within distinct niches of the intervertebral disc. Matrix Biol 2014; 37: 124–30.
Barney LE, Dandley EC, Jansen LE, et al. A cell-ECM screening method to predict breast cancer metastasis. Integr Biol (Camb) 2015; 7: 198–212.
Tung JC, Barnes JM, Desai SR, et al. Tumor mechanics and metabolic dysfunction. Free Radic Biol Med 2015; 79: 269–80.
Naba A, Clauser KR, Lamar JM, et al.Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. Elife 2014; 3: e01308.
Naba A, Clauser KR, Whittaker CA, et al.Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer 2014; 14: 518.
Zhu J, Liang L, Jiao Y, et al. Enhanced invasion of metastatic cancer cells via extracellular matrix interface. China Physical Sciences-Oncology Alliance. PLoS One 2015; 10: e0118058.
Wirtz D,Konstantopoulos K,Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer 2011; 11: 512–22.
van Kempen LC, Rhee JS, Dehne K, et al. Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation 2002; 70: 610–23.
Faurobert E, Bouin AP, Albiges-Rizo C. Microenvironment, tumor cell plasticity, and cancer. Curr Opin Oncol 2015;
: 64–70.
Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. Breast 2013; 22: S66–72.
Insua-Rodríguez J, Oskarsson T. The extracellular matrix in breast cancer. Adv Drug Deliv Rev 2016; 97: 41–55.
Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 2010; 86: 236–42.
Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013; 123: 3664–71.
Hanna SC, Krishnan B, Bailey ST, et al. HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 2013; 123: 2078–93.
Gilkes DM, Bajpai S, Chaturvedi P, et al. Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem 2013; 288: 10819–29.
Catalano V, Turdo A, Di Franco S, et al. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 2013; 23: 522–32.
Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 2014; 14: 430–9.
Lopez JI, Kang I, You WK, et al. In situ force mapping of mammary gland transformation. Integr Biol 2011: 3 (9): 910–21.
Chang YN, Zhang K, Hu ZM, et al. Hypoxia-regulated lncRNAs in cancer. Gene 2016; 575: 1–8.
Semenza GL. The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta 2016; 1863: 382–91.
Semenza GL, Ruvolo PP. Introduction to tumor microenvironment regulation of cancer cell survival, metastasis, inflammation, and immune surveillance. Biochim Biophys Acta 2016; 1863: 379–81.
Mao Y, Keller ET, Garfield DH, et al. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013; 32: 303–15.
Rong L, Li R, Li S, et al. Immunosuppression of breast cancer cells mediated by transforming growth factor-β in exosomes from cancer cells. Oncol Lett 2016; 11: 500–4.
Cui W, Zhou J, Dehne N, et al. Hypoxia induces calpain activity and degrades SMAD2 to attenuate TGFβ signaling in macrophages. Cell Biosci 2015; 5: 36.
Lee SL,Ryu H,Son AR, et al.TGF-β and hypoxia/reoxygenation promoteradioresistanceof A549 lung cancer cells through activation of Nrf2 and EGFR. Oxid Med Cell Longev 2016; 2016: 6823471.
Iwadate Y, Matsutani T, Hirono S, et al. Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma. J Neurooncol 2016; 18 [Epub ahead of print].
Wynn TA,Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30: 245–57.
Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metastasis 2009; 26: 35–49.
Descot A, Oskarsson T. The molecular composition of the metastatic niche. Exp Cell Res 2013; 319: 1679–86.
Santamaria-Martínez A, Huelsken J. The niche under siege: novel targets for metastasis therapy. J Intern Med 2013; 274: 127–36.
Sleeman JP. The metastatic niche and stromal progression. Cancer Metastasis Rev 2012; 31: 429–40.
Lowy CM,Oskarsson T. Tenascin C in metastasis: A view from the invasive front. Cell Adh Migr 2015; 9: 112–24.
Oskarsson T, Acharyya S, Zhang XH, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17: 867–74.
Huang CP, Lu J, Seon H, et al. Engineering microscale cellular niches for three-dimensional multicellular co-cultures. Lab Chip 2009; 9: 1740–8.
Chiovaro F,Martina E,Bottos A, et al. Transcriptional regulation oftenascin-Wby TGF-beta signaling in the bone metastatic niche of breast cancer cells. Int J Cancer 2015; 137: 1842–54.
Wang Z, Xiong S, Mao Y, et al. Periostin promotes immunosuppressive premetastatic niche formation to facilitate breast tumour metastasis. J Pathol 2016 [Epub ahead of print].
Ratajczak-Wielgomas K, Dziegiel P. The role of periostin in neoplastic processes. Folia Histochem Cytobiol 2015; 53: 120–32.
Kii I,Nishiyama T,Li M, et al. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem 2010; 285: 2028–39.
Oskarsson T, Massagué J. Extracellular matrix players in metastatic niches. EMBO J 2012; 31: 254–6.
Eyles J, Puaux AL, Wang X, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010; 120: 2030–9.
Wong CC,Gilkes DM,Zhang H, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A 2011; 108: 16369–74.
Pietilä M, Ivaska J, Mani SA. Whom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment? Cancer Lett 2016; 380: 359–68.
Kalluri R,Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776–84.
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420–8.
Yang J, Zhang X, Zhang Y, et al. HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. J Exp Clin Cancer Res 2016; 35: 26.
Ungewiss C, Rizvi ZH, Roybal JD, et al. The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK
signaling, cancer cell invasion and metastasis through CRKL. Sci Rep 2016; 6: 18652.
Zong W, Yu C, Wang P, et al. Overexpression of SASH1 inhibits TGF-β1-Induced EMT in gastric cancer cells. Oncol Res 2016; 24: 17–23.
AbulaitiA,Shintani Y,Funaki S, et al. Interaction between nonsmall-cell lung cancer cells and fibroblasts via enhancement of TGF-β signaling by IL-6. Lung Cancer 2013; 82: 204–13.
Fuxe J, Karlsson MC. TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 2012; 22: 455–61.
Su S, Liu Q, Chen J, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014; 25: 605–20.
Bonde AK, Tischler V, Kumar S, et al. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer 2012; 12: 35.
SchweigerT,Nikolowsky C,Starlinger P, et al. Stromal expression ofheat-shockprotein 27 is associated with worse clinical outcome in patients with colorectal cancer lung metastases. PLoS One 2015; 10: e0120724.
KnowlesLM,GurskiLA,Engel C, et al. Integrin αvβ3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis. Cancer Res 2013; 73: 6175–84.
Lv H, Liu R, Fu J, et al.Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway. Cell Cycle 2014; 13: 2962–74.
Zhu J, Pan X, Zhang Z, et al. Downregulation of integrinlinked kinase inhibits epithelial-to-mesenchymal transition and metastasis in bladder cancer cells. Cell Signal 2012; 24: 1323–32.
Yang J, Zhang X, Zhang Y, et al. HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. J Exp Clin Cancer Res 2016; 35: 26.
Huang M, Wang L, Chen J, et al. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxiainducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery. Int J Oncol 2016; 48: 2144–54.
Peranzoni E, Rivas-Caicedo A, Bougherara H, et al. Positive and negative influence of the matrix architecture on antitumor immune surveillance. Cell Mol Life Sci 2013; 70: 4431–48.
Monboisse JC,Oudart JB,Ramont L, et al. Matrikines from basement membrane collagens: a new anti-cancer strategy. Biochim Biophys Acta 2014; 1840: 2589–98.
Huang JY, Cheng YJ, Lin YP, et al. Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: the role of tenascin-C in immune suppression. J Immunol 2010; 185: 1450–9.
Caruana I, Savoldo B, Hoyos V, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 2015; 21: 524–9.
Wolf K,Müller R,Borgmann S, et al. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood 2003; 102: 3262–9.
Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 2013; 13: 788–99.
Ciechomska M, Wilson CL, Floudas A, et al. Antigen-specific B lymphocytes acquire proteoglycan aggrecan from cartilage extracellular matrix resulting in antigen presentation and CD4+ T-cell activation. Immunology 2014; 141: 70–8.
Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006; 35:
–83.
Wight TN, Kang I, Merrilees MJ. Versican and the control of inflammation. Matrix Biol 2014; 35: 152–61.
Onken J, Moeckel S, Leukel P, et al. Versican isoform V1 regulates proliferation and migration in high-grade gliomas. J Neurooncol 2014; 120: 73–83.
Faurobert E, Bouin AP, Albiges-Rizo C. Microenvironment, tumor cell plasticity, and cancer. Curr Opin Oncol 2015;
: 64–70.
Hartmann N, Giese NA, Giese T, et al. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. Clin Cancer Res 2014; 20: 3422–33.
Górski A, Castronovo V, Stepień-Sopniewska B, et al. Depressed immune surveillance against cancer: role of deficient T cell: extracellular matrix interactions. Cell Adhes Commun 1994; 2: 225–33.
Jiang D, Lim SY. Influence of immune myeloid cells on the extracellular matrix during cancer metastasis. Cancer Microenviron 2016; 9: 45–61.
Acerbi I, Cassereau L, Dean I, et al. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) 2015; 7: 1120–34.
Narunsky L, Oren R, Bochner F, et al. Imaging aspects of the tumor stroma with therapeutic implications. Pharmacol Ther 2014;
: 192–208.
Wang Z, Li S, Li F, et al. Identification and function analysis of a novel vascular endothelial growth factor, LvVEGF3, in the Pacific whiteleg shrimp Litopenaeus vannamei. Dev Comp Immunol 2016; 63: 111–20.
Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic instability. Genome Integr 2013; 4: 5.
Jin F, Brockmeier U, Otterbach F, et al. New insight into the SDF-1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell CXCR4 are required fortumor cell intravasation. Mol Cancer Res 2012; 10: 1021–31.
Zhao BC, Wang ZJ, Mao WZ, et al. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol 2011; 17: 2389–96.
Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Perspect Med 2012; 2: a006544.
Balcioglu HE, van de Water B, Danen EH. Tumor-induced remote ECM network orientation steers angiogenesis. Sci Rep 2016; 6: 22580.
Nagy JA, Shih SC, Wong WH, et al. Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay. Methods Enzymol 2008; 444: 43–64.
Dvorak HF. Tumor stroma, tumor blood vessels, and antiangiogenesis therapy. Cancer J 2015; 21: 237–43.
Huang Y, Song N, Ding Y, et al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res 2009; 69: 7529–37.
Hayashi Y, Call MK, Chikama T, et al. Lumican is required for neutrophil extravasation following corneal injury and wound healing. J Cell Sci 2010; 123: 2987–95.
Nikitovic D, Papoutsidakis A, Karamanos NK, et al. Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response. Matrix Biol 2014; 35: 206–14.
Liu Y, Li F, Gao F, et al. Periostin promotes tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling. Oncotarget 2016 [Epub ahead of print].
Wang Z, Xiong S, Mao Y, et al. Periostin promotes immunosuppressive premetastatic niche formation to facilitate breast tumour metastasis. J Pathol 2016 [Epub ahead of print].
Shin Y, Han S, Chung E, et al.Intratumoral phenotypic heterogeneity as an encourager of cancer invasion. Integr Biol (Camb) 2014; 6: 654–61.
